Data from a multi-institutional research effort shed light on opportunities to improve the safety of adding immunotherapy to conventional curative therapies, underscoring the importance of close monitoring and multidisciplinary management. Led by a Roswell Park Comprehensive Cancer Center fellow, the work, newly published in The Lancet Oncology, demonstrates that the addition of immune checkpoint inhibition (ICI) to perioperative therapy was associated with increased treatment-related adverse events as well as an increasing trend of fatal toxicity.

Roswell Park's Mary Reid, PhD, spoke alongside Rep. Debbie Wasserman Schultz, representatives from The American Lung Association, GO2 for Lung Cancer and LUNGevity Foundation and lung cancer patient advocates who gathered on Capitol Hill to demand national action to reduce suffering and death from lung cancer.

Three competitive National Cancer Institute grants totaling $13.5 million will support the Roswell Park Comprehensive Cancer Center team leading a multi-institutional effort aimed at improving the potential of immune checkpoint inhibitors, in close collaboration with experts from the University of Rochester’s Wilmot Cancer Institute and Kaiser Permanente Northern California Division of Research.